Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMTX: Moderna Collaboration
https://fintel.io/doc/sec-immatics-nv-1809196-6k-2023-september-11-19611-8721?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On September 7, 2023, Immatics Biotechnologies GmbH, a subsidiary of Immatics N.V. (the “Company” or “Immatics”), entered into a Master Collaboration and License Agreement (the “Master Collaboration and License Agreement”) with ModernaTX, Inc., a subsidiary of Moderna, Inc. (“Moderna”), relating to three research programs for the development and commercialization of products employing Immatics’ and Moderna’s technologies: (i) a collaboration to discover and develop mRNA-based TCER therapeutics against targets of interest to Moderna (the “TCER Program”); (ii) the validation, generation and application of data useful for the research and development of cancer vaccines (the “Database/Vaccine Program”); and (iii) a combination therapy clinical trial with respect to IMA203 and a Moderna mRNA-based cancer vaccine (the “Clinical Combo Program”). Each research program will be governed by the Master Collaboration and License Agreement and a project agreement as described below.
Pursuant to the Master Collaboration and License Agreement, following Hart-Scott-Rodino Antitrust Improvements Act clearance, Moderna will pay to Immatics a $120 million upfront payment. In addition, as described below, Immatics may be eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.
With respect to the TCER Program, pursuant to the Master Collaboration and License Agreement and the TCER Collaboration Project Agreement between the parties (the “TCER Project Agreement”), the parties will conduct the TCER Program for the research and development of TCERs with respect to HLA-presented peptide targets derived from an agreed upon number of proteins selected by Moderna. Immatics will be responsible for, and be reimbursed the cost of, TCER identification, validation and engineering to generate the applicable TCER sequence and preclinical studies in accordance with the applicable mutually agreed research plan, while Moderna will be responsible for, and bear the cost of, developing, manufacturing and commercializing the applicable products containing or comprising such TCERs; provided that Immatics has a right to co-fund the development and commercialization of certain products by making an opt-in payment in exchange for profit and loss sharing on such products. Immatics will grant to Moderna an exclusive, worldwide sublicensable license to develop, manufacture and commercialize any product (or that contain any product) developed under the TCER Project Agreement. For each target, depending on certain product characteristics, Immatics may be eligible to receive milestone payments of up to a mid-eight-digit amount upon the achievement of certain development milestones and up to a mid-nine-digit amount upon the achievement of certain regulatory and commercial milestones. In addition, during the royalty term (as described below) and depending on certain product characteristics, Immatics will be eligible to receive tiered, mid-single-digit to low-double-digit percentage royalties on worldwide net sales of the applicable product, which royalty percentages are subject to reduction in a given country under certain circumstances. A royalty term with respect to a product under the TCER Program in a given country begins upon the first commercial sale of such product in such country and terminates on the latest of the expiration of regulatory exclusivity, the expiration of valid patent claims covering such product, and 10 years after first commercial sale of the product in a given country. The TCER Project Agreement will expire upon expiration of the last royalty term contemplated by the TCER Project Agreement. During the term of the TCER Program, Immatics has certain exclusivity and notification obligations to Moderna, and its ability to develop, manufacture and commercialize certain cell therapy products that bind to the targets subject to the TCER Project Agreement is limited by the TCER Project Agreement.
With respect to the Database/Vaccine Program, pursuant to the Master Collaboration and License Agreement and the Database/Vaccine Collaboration Project Agreement between the parties (the “Database/Vaccine Project Agreement”), the parties will use Immatics’ XPRESIDENT platform to (i) generate reports for proteins or cancer vaccine candidates and validate cancer vaccine candidates (the “Database Query Program”), (ii) select peptides for respect to specific tumor types selected by Moderna for the development of cancer vaccines (the “Shared Vaccine Program”), and (iii) provide certain epitope prediction data for potential development and validation of cancer vaccines (the “Optimized Vaccine Program”). The term of these programs can be up to approximately five years. Immatics will grant to Moderna an exclusive, worldwide sublicensable license to develop, manufacture and commercialize any Shared Vaccine product or Optimized Vaccine product developed under the Database/Vaccine Project Agreement. Immatics may be eligible to receive (i) depending on the characteristics of the cancer vaccine, certain milestone payments under the Database Query Program, (ii) for each resulting cancer vaccine in the Shared Vaccine Program and the Optimized Vaccine Program, depending on certain product characteristics, up to a low-eight-digit amount upon the achievement of certain development milestones and up to a low-nine-digit amount upon the achievement of certain regulatory and commercial milestones, and (iii) for each resulting cancer vaccine in the Shared Vaccine Program, during the royalty term (as described below) and depending on certain product characteristics, tiered, low- to mid-single-digit percentage royalties on worldwide net sales of such product. A royalty term with respect to a cancer vaccine in the Shared Vaccine Program and the Optimized Vaccine Program in a given country begins upon the first commercial sale of such product in such country and
terminates on the latest of the expiration of regulatory exclusivity, the expiration of valid patent claims covering such product, and 10 years after first commercial sale of the product in a given country. During the term of the Database/Vaccine Program, Immatics has certain exclusivity obligations to Moderna, and its ability to develop certain cancer vaccines is limited by the Database/Vaccine Project Agreement.
With respect to the Clinical Combo Program, pursuant to the Master Collaboration and License Agreement and the Combination Collaboration Project Agreement between the parties (the “Clinical Combo Project Agreement”), the parties will collaborate to develop a combination therapy of IMA203 (or IMA203CD8) and a Moderna mRNA-based cancer vaccine. Immatics will be responsible for, and the parties will share the cost of, development activities in accordance with the applicable mutually agreed research plan. For so long as the parties are conducting the combination therapy clinical trial, Immatics has certain exclusivity obligations to Moderna, and its ability to develop, manufacture and commercialize combination products that involve a cancer vaccine and a cell therapy product that binds to the target of IMA203 is limited by the Clinical Combo Project Agreement.
The foregoing descriptions of the Master Collaboration and License Agreement and the project agreements thereunder do not purport to be complete and are qualified in their entirety by reference to the full text of the applicable agreements, which will be filed as an exhibit to the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 or a Report on Form 6-K.
In connection with the foregoing, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, and made available an updated investor presentation on its website, a copy of which is attached hereto as Exhibit 99.2.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than Exhibit 99.1 and 99.2 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351, 333-240260 and 333-274218) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
14,46 a share! Very good sign in my opinion!
Looks like for most of June, it's been hugging the upper Bollinger/Keltner Channel ( both are similar)
The trend is looking positive ( however we know that can change at anytime), presentations and AGM are June 20/23 - few days from now.
Chart looking very promising now...hope we'll see new alltimehigh soon! But I believe...Biotech is getting popular at the moment - could give us some support too...
Looks interesting...Something coming up!
IMTX: Volume spike Friday June 16/23
Just over 2 million changed hands around $12.40 in the snap of a finger.
Looks like June is a heavy presentation month as well as the Annual General Meeting in Amsterdam, Netherlands on June 20/23.
(Are you going to that?)
https://investors.immatics.com/events-presentations
Yes, i noticed the volume as well and nice to see double digits/volume.
Nice volume today... something coming up?....
Did you notice this?
https://flashalert.me/?symbol=IMTX&source=SEC&referer=https://twitter.com/&url=https://www.sec.gov/Archives/edgar/data/1696029/000121390023010278/ea173206-13ga2dievini_immat.htm&s3=IMTX/2023-02-10/16-53-17_000000/SC%2013G/A/a7fde3b93846d15ce2863fe53eb01575/0001213900-23-010278-index.htm
Do you know anything about this organization?
https://www.dievini.de/
They are the ones reporting in the above sec filing to owning 17+ million shares of IMTX!
Good sign! Only question of time this will run...
https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-neurocrine-nbix-and-immatics-imtx-1032070272
Immatics (IMTX)
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Immatics today. The company’s shares closed last Friday at $8.34.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of 3.0% and a 40.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Better Therapeutics, Inc., and Emergent Biosolutions.
Currently, the analyst consensus on Immatics is a Moderate Buy with an average price target of $22.50.
HUGE INCREASE in institutional holdings
Check these links out:
Today's 13G filing:
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/90162993/schedule-13g-br-sc-13g
" AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,957,794" ( an increase of 4,079,134)
As of 09/30/22 re: courtesy of nasdaq
Wellington MGMT. ( 5th on the list)
1,878,660
https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings
This puts Wellington MGMT as the largest known shareholder, at the moment.
Volume and stock price turning positive!
I believe IMTX will be on the agenda for discussion here next week:
https://www.bryangarnier.com/bryan-garnier-innovation-series-tcr-therapeutics/
Stay well bro.
Nice new presentation on the website...
PPS not to understand here...great chances for new investors...
Solid support on the BID
At the moment at least, these things can change in a heartbeat though.
Another article:
https://www.evaluate.com/vantage/articles/news/trial-results/prame-looks-real-deal
TCRX targetting Mage and Prame
TCRX presentation here:
https://ir.tscan.com/static-files/e37317c4-d6a7-48c3-9071-c11d7cfd222c
see page 14 of 43 info on CD8 effect - VERY POSITIVE FOR IMTX, imo.
What i found interesting about the interim data that was recently released was the Phase 1b cohort had 80% confirmed objective response. That was the IMA203 alone with the 4 and 5 dose level escalation. Allbeit a low sample - only 5 patients, however interesting data.
Given the early data of IMA203 alone (80% objective response for dose level 4 and 5) The IMA203 +CD8 (t-cell helper) and/or IMA203 plus Opdivo (checkpoint inhibitor - BMS) has serious potential to be a breakout therapy, imo.
The data for IMA 203 CD8 and Opdivo should be out soon, if not December i would say 1st quarter of 2023, imo.
(IMTX and TCRX = 2 top notch biotechs in TCR-T, imo.)
Thank u! In the near future I think we' ll see a strong development here. I have the feeling we fly under the radar for the moment. But once we get started...we have a strong pipeline here..."only" one success and we talk about 100plus in my opinion...
FY 2022 earnings estimate update:
https://www.marketbeat.com/instant-alerts/nasdaq-imtx-analyst-earnings-estimates-2022-11-2-3/
"Immatics (NASDAQ:IMTX - Get Rating) - Analysts at Chardan Capital boosted their FY2022 earnings estimates for Immatics in a report issued on Monday, November 21st. Chardan Capital analyst Y. Livshits now expects that the company will earn $0.81 per share for the year, up from their prior forecast of $0.23. Chardan Capital has a "Buy" rating and a $28.00 price target on the stock. The consensus estimate for Immatics' current full-year earnings is $0.44 per share. Chardan Capital also issued estimates for Immatics' FY2023 earnings at ($1.31) EPS. "
Interesting info here regarding a Phase 2 trial over at PDS Biotech:
https://ih.advfn.com/stock-market/NASDAQ/pds-biotechnology-PDSB/stock-news/89544084/pds-biotech-announces-100-clinical-response-in-ce
Excerpt 1
"As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8+ T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8+ T cells are important mediators of antigen-specific immunity."
Remember IMTX held back the results from the IMA203 +CD8 part of the trial. Might be interesting results - also Opdivo + IMA 203 results ( BMS) held back.
IMTX trials sre still in an early phase, imo. TCR-T category still early as well, imo.
Not sure if IMTX will be presenting at the ASH. TScan is and is also in the TCR-T category with a very strategic approach, imo.
https://www.hematology.org/meetings/annual-meeting
IMTX Top 5 Institutional Holders:
OWNER NAME / DATE / SHARES HELD
BAKER BROS. ADVISORS LP 09/30/2022 4,423,731
NANTAHALA CAPITAL MANAGEMENT, LLC 09/30/2022 2,713,968
PERCEPTIVE ADVISORS LLC 09/30/2022 2,500,000
FEDERATED HERMES, INC. 09/30/2022 2,106,000
WELLINGTON MANAGEMENT GROUP LLP 09/30/2022 1,878,660
TCR Bispecifics Programs
TCER® IMA401 (MAGEA4/8) – IMA401 is being developed in collaboration with Bristol Myers Squibb; 9 centers in Germany have been activated and are enrolling patients.
Interesting website here on History of BMS / click on "competitors" for further data:
https://www.zippia.com/bristol-myers-squibb-careers-1752/history/
On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration. Initially announced on February 20, 2020, the terms of the agreement included a €45 Million (~$50 Million) upfront payment to Immatics and the potential for additional milestone and royalty payments in return for access to two of Immatics’ TCR-T programs. As communicated to Immatics, GSK’s decision was made unrelated to the programs and the progress achieved in the collaboration to date. The termination will be effective on December 26, 2022.
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89581771/immatics-announces-third-quarter-2022-financial-r
If you go back to this article here (Oct.25/22), had they included Immatics in the article it would have been more definitively clear that GSK was exiting the TCR-T space, imo. Most likely it didn't fit with their business model.
https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/
Article is not a free article, link here / intro:
https://www.science.org/doi/10.1126/scitranslmed.abo6135#core-collateral-purchase-access
COL-ing out TCR-Ts
Adoptive T cell therapy targeting neoantigens is a promising new therapeutic technique; however, the lack of shared neoantigens across patients limits the use of this technique. To overcome this, Kim et al. identified a shared pan-cancer collagen type VI a-3 (COL6A3) epitope that was presented on tumor stroma and was the result of an alternative splicing event. They created affinity-enhanced T cell receptor T (TCR-T) cells and treated mice in vivo to show regression in tumors that expressed physiological levels of the targeted pHLA without toxicity to normal cells. This method represents a promising treatment to target multiple cancer types and warrants further clinical investigation.
Abstract
T cell receptor (TCR)–based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide–human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed on healthy tissue in combination with high-affinity TCRs that when introduced into T cells can redirect T cells to eliminate tumor but not healthy tissue is a key requirement for safe and efficacious TCR-based therapies. To discover promising shared tumor antigens that could be targeted via TCR-based adoptive T cell therapy, we employed population-scale immunopeptidomics using quantitative mass spectrometry across ~1500 tumor and normal tissue samples. We identified an HLA-A*02:01-restricted pan-cancer epitope within the collagen type VI a-3 (COL6A3) gene that is highly presented on tumor stroma across multiple solid cancers due to a tumor-specific alternative splicing event that rarely occurs outside the tumor microenvironment. T cells expressing natural COL6A3-specific TCRs demonstrated only modest activity against cells presenting high copy numbers of COL6A3 pHLAs. One of these TCRs was affinity-enhanced, enabling transduced T cells to specifically eliminate tumors in vivo that expressed similar copy numbers of pHLAs as primary tumor specimens. The enhanced TCR variants exhibited a favorable safety profile with no detectable off-target reactivity, paving the way to initiate clinical trials using COL6A3-specific TCRs to target an array of solid tumors.
From the 3rd quarter 10Q:
IND = Investigational New Drug
ACTengine® IMA204 (COL6A3 exon 6) – Immatics and the University of Pennsylvania co-authored a research paper published in the peer-reviewed journal, Science Translational Medicine, that highlighted Immatics’ differentiated approach to develop TCR-based therapies through its proprietary discovery platforms, XPRESIDENT® and XCEPTOR®. With this approach, Immatics identified a novel proprietary HLA-A*02:01-presented target generated by a tumor-specific alternative splicing event in the abundantly expressed protein collagen type VI alpha-3 (COL6A3). This target is expressed at high target density across multiple solid cancer indications and specific to the tumor stroma. Targeting tumor stroma provides an innovative therapeutic opportunity to disrupt the tumor microenvironment. Immatics has engineered target-specific, affinity-enhanced proprietary TCRs, one of them being CD8-independent and thus facilitating targeting of COL6A3 exon 6 positive cells by both CD4 and CD8 T cells. The TCR-T candidate, IMA204 was able to eliminate tumor cells at physiological target levels in in vitro studies and in vivo mouse models. Due to Immatics focusing its clinical resources on the three IMA203 Phase 1b cohorts as well as accelerating the clinical development for the PRAME TCER® IMA402, the company has delayed the IND submission for an ACTengine® candidate directed against COL6A3 exon 6.
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89581771/immatics-announces-third-quarter-2022-financial-r
But it seems to be a strategic decision from GSK and has a least nothing to do with Immatics. Reading the news I feel confident Immatics will have success in the future and these levels of pps are history in the near future...At this stage the company is already much more worth....half of the marketcap do they in cash....
It is Opdivo. From memory, the first patient was dosed back in May.
Thanks it's here in black and white:
https://ca.finance.yahoo.com/news/immatics-announces-third-quarter-2022-120000183.html
Cohort B – The first patient in the Phase 1b expansion cohort B was treated with IMA203 in combination with the PD-1 immune checkpoint inhibitor nivolumab in May 2022. Patients will be treated at RP2D.
Nivolumab / Opdivo = Bristol Myers Squibb
https://www.opdivo.com/
That better explains the recent 100 million + capital raise.
Revenue from GSK all dried up.
Confirmed here as well.
https://www.biospace.com/article/gsk-continues-to-thin-cell-therapy-pipeline-as-it-ends-partnership-with-immatics/
Do we know which checkpoint inhibitor IMTX was working with, with the IMA203 + checkpoint inhibitor trial?
Oh, that could make sense. I think that's possible. But in this case this could explode next year. I see here a good chance for a tenbagger and more...the marketcap for now is nothing regarding to the potential in the future...
I concur with that analysis.
What i find interesting is that they reported interim clinical data on IMA203 on October 10/22
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257173/immatics-reports-interim-clinical-data-update-on-a
but held back the data on IMA203 + checkpoint inhibitor and IMA203CD8 - pushing the release of that data into 2023:
"we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8. As we continue to shift our focus from Phase 1a to Phase 1b, we look forward to reporting meaningful data throughout 2023, "
Then the capital raise at $10.09 on the same day Oct.10/22
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257170/immatics-announces-110-million-underwritten-offer
Is it just my imagination, or could the sequence of events ( IMA203 limited clinical data Oct.10/22 - capital raise Oct.10/22 - GSK cutting ties with Lyell and Adaptimmune Oct.25/22) indicate that some positive to very positive news is afoot (IMA203 checkpt. , IMA203CD8) with IMTX?
GSK maybe taking a bigger position before the wildly amazing news is released in 2023 - just speculating a little, because imo, the stock is acting as though big buyers are accumulating.
Oh, thank you!
That is interesting! For my opinion the pps has to be much higher, already at this stage. But Biotech often needs only a view days to make 100% and more. Once this starts we will never see that niveau again...
Interesting development here with GSK
https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/
Excerpt from article:
"GSK did not respond to BioPharma Dive’s request for comment. The company has another cell therapy deal with German biotech Immatics Biotechnologies that’s focused on solid tumors."
The previous presentation coupled with, the recent capital raise, and now this info are all positive indicators for IMTX, imo.
Looks very promising and professional!
New Corporate presentation October 18/22
https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6
Looks excellent imo.
Both news are great in my eyes! I believe it could be the starting point of a longer nice development here....
IMTX Capital Raise:
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257170/immatics-announces-110-million-underwritten-offer
Some big dollars and big institutional involvement here with IMTX.
I hope so,... and turning back to accumulation with an uptick in stock price looks positive.
Nice to see double digits again, however the short position is still on the rise by +/- 280,000 shares as of 09/15/22 in comparison to the amount reported on 08/31/22
https://www.nasdaq.com/market-activity/stocks/imtx/short-interest
Slightly bearish signal, imo, however sophisticated hedge funds can sometimes utilize short positions with options in their investment strategies, so i have heard, so the short position may not be too much of a concern.
Looks a little like consolidation is over....
Tracking Baker Bros. portfolio - IMTX
https://seekingalpha.com/article/4543704-baker-brothers-portfolio-q2-2022-update
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
154
|
Created
|
07/06/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |